Literature DB >> 30738495

Acute tubulointerstitial nephritis caused by rifampicin: An increasing and often overlooked side effect in elderly patients
.

Manabu Nagata, Goh Ohji, Kentaro Iwata.   

Abstract

BACKGROUND: There are many side effects of antituberculous drugs, however, renal failure is relatively rare. Therefore, this side effect is thought to be unrecognized by most physicians. We experienced one case of acute renal failure caused by antituberculous therapy (rifampicin). CASE REPORT: A 64-year-old Japanese male developed tuberculous pleuritis. Six weeks after starting isoniazid (INH), rifampicin (RFP), and ethambutol (EB), his renal function worsened. We temporarily stopped antituberculous therapy, but the patient's renal failure did not improve, and he was admitted to our hospital for renal biopsy. Renal pathology indicated a diagnosis of acute interstitial nephritis. After starting prednisolone, his renal function slowly improved while INH was continued. A drug-induced lymphocyte stimulation test (DLST) of the antituberculous drugs did not reveal the causative agent. However, we consider RFP to be the most likely culprit.
CONCLUSION: In recent reports, renal failure is not a rare complication during antituberculous treatment in the elderly population. Physicians who are involved with the administration of antituberculous therapy have to be aware of this side effect. DLST is not useful for identifying the causative agent of antituberculous drug side effects. Leukocyte migration test may be more useful than DLST for this purpose, but further clinical studies are necessary to verify effectiveness.
.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30738495     DOI: 10.5414/CP203287

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN: 0946-1965            Impact factor:   1.366


  1 in total

1.  Acute Tubular Necrosis and Thrombocytopenia Associated With Rifampin Use: Case Report and Review.

Authors:  Emma L Smith; Laura Bywater; Rebecca Pellicano; Grant A Jenkin; Tony M Korman
Journal:  Open Forum Infect Dis       Date:  2022-05-17       Impact factor: 4.423

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.